These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 22634442)

  • 1. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in patients with chronic pulmonary diseases: a matched case-control study.
    Vila-Corcoles A; Ochoa-Gondar O; Rodriguez-Blanco T; Gutierrez-Perez A; Vila-Rovira A;
    Hum Vaccin Immunother; 2012 May; 8(5):639-44. PubMed ID: 22634442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study.
    Vila-Corcoles A; Salsench E; Rodriguez-Blanco T; Ochoa-Gondar O; de Diego C; Valdivieso A; Hospital I; Gomez-Bertomeu F; Raga X
    Vaccine; 2009 Mar; 27(10):1504-10. PubMed ID: 19171174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study.
    Vila-Córcoles A; Ochoa-Gondar O; Hospital I; Ansa X; Vilanova A; Rodríguez T; Llor C;
    Clin Infect Dis; 2006 Oct; 43(7):860-8. PubMed ID: 16941367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older.
    Vila-Corcoles A; Ochoa-Gondar O; Guzmán JA; Rodriguez-Blanco T; Salsench E; Fuentes CM;
    BMC Infect Dis; 2010 Mar; 10():73. PubMed ID: 20298596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive disease and hospital-treated pneumonia among people aged ≥65 years: a retrospective case-control study.
    Leventer-Roberts M; Feldman BS; Brufman I; Cohen-Stavi CJ; Hoshen M; Balicer RD
    Clin Infect Dis; 2015 May; 60(10):1472-80. PubMed ID: 25669354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of pneumococcal vaccination: a comparison of vaccination rates in patients with bacteremic and nonbacteremic pneumococcal pneumonia.
    Musher DM; Rueda-Jaimes AM; Graviss EA; Rodriguez-Barradas MC
    Clin Infect Dis; 2006 Oct; 43(8):1004-8. PubMed ID: 16983612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥ 60 years: 3 years of follow-up in the CAPAMIS study.
    Ochoa-Gondar O; Vila-Corcoles A; Rodriguez-Blanco T; Gomez-Bertomeu F; Figuerola-Massana E; Raga-Luria X; Hospital-Guardiola I
    Clin Infect Dis; 2014 Apr; 58(7):909-17. PubMed ID: 24532544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of the pneumococcal polysaccharide vaccine in preventing pneumonia in the elderly.
    Domínguez A; Izquierdo C; Salleras L; Ruiz L; Sousa D; Bayas JM; Nebot M; Varona W; Celorrio JM; Carratalà J;
    Eur Respir J; 2010 Sep; 36(3):608-14. PubMed ID: 20075048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective effect of pneumococcal vaccine against death by pneumonia in elderly subjects.
    Vila-Córcoles A; Ochoa-Gondar O; Llor C; Hospital I; Rodríguez T; Gómez A
    Eur Respir J; 2005 Dec; 26(6):1086-91. PubMed ID: 16319340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of 23-valent pneumococcal polysaccharide vaccine and seasonal influenza vaccine for pneumonia among the elderly - Selection of controls in a case-control study.
    Kondo K; Suzuki K; Washio M; Ohfuji S; Fukushima W; Maeda A; Hirota Y;
    Vaccine; 2017 Aug; 35(36):4806-4810. PubMed ID: 28818473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 23-valent pneumococcal polysaccharide vaccine is effective in elderly adults over 75 years old--Taiwan's PPV vaccination program.
    Tsai YH; Hsieh MJ; Chang CJ; Wen YW; Hu HC; Chao YN; Huang YC; Yang CT; Huang CC
    Vaccine; 2015 Jun; 33(25):2897-902. PubMed ID: 25936662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of polysaccharide pneumococcal vaccine in HIV-infected patients: a case-control study.
    Peñaranda M; Falco V; Payeras A; Jordano Q; Curran A; Pareja A; Samperiz G; Dalmau D; Ribera E; Riera M
    Clin Infect Dis; 2007 Oct; 45(7):e82-7. PubMed ID: 17806042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of pneumococcal polysaccharide vaccine in older adults.
    Jackson LA; Neuzil KM; Yu O; Benson P; Barlow WE; Adams AL; Hanson CA; Mahoney LD; Shay DK; Thompson WW;
    N Engl J Med; 2003 May; 348(18):1747-55. PubMed ID: 12724480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of pneumococcal vaccination for elderly people in Catalonia, Spain: a case-control study.
    Dominguez A; Salleras L; Fedson DS; Izquierdo C; Ruiz L; Ciruela P; Fenoll A; Casal J
    Clin Infect Dis; 2005 May; 40(9):1250-7. PubMed ID: 15825026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of pneumococcal vaccination in older adults with chronic respiratory diseases: results of the EVAN-65 study.
    Ochoa-Gondar O; Vila-Corcoles A; Ansa X; Rodriguez-Blanco T; Salsench E; de Diego C; Raga X; Gomez F; Valdivieso E; Fuentes C; Palacios L;
    Vaccine; 2008 Apr; 26(16):1955-62. PubMed ID: 18343541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical effectiveness of pneumococcal polysaccharide vaccine in men: California Men's Health Study.
    Hechter RC; Chao C; Jacobsen SJ; Slezak JM; Quinn VP; Van Den Eeden SK; Tseng HF
    Vaccine; 2012 Aug; 30(38):5625-30. PubMed ID: 22789510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of pneumococcal polysaccharide vaccine on incidence and mortality after pneumonia in adults aged ≥60 years-a population-based retrospective cohort study.
    Kolditz M; Schmitt J; Pletz MW; Tesch F
    Clin Microbiol Infect; 2018 May; 24(5):500-504. PubMed ID: 28830805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of vaccination with 23-valent pneumococcal polysaccharide vaccine in preventing hospitalization with laboratory confirmed influenza during the 2009-2010 and 2010-2011 seasons.
    Domínguez A; Castilla J; Godoy P; Delgado-Rodríguez M; Saez M; Soldevila N; Astray J; Mayoral JM; Martín V; Quintana JM; González-Candelas F; Galán JC; Tamames S; Castro A; Baricot M; Garín O; Pumarola T;
    Hum Vaccin Immunother; 2013 Apr; 9(4):865-73. PubMed ID: 23563516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.
    Bonten MJ; Huijts SM; Bolkenbaas M; Webber C; Patterson S; Gault S; van Werkhoven CH; van Deursen AM; Sanders EA; Verheij TJ; Patton M; McDonough A; Moradoghli-Haftvani A; Smith H; Mellelieu T; Pride MW; Crowther G; Schmoele-Thoma B; Scott DA; Jansen KU; Lobatto R; Oosterman B; Visser N; Caspers E; Smorenburg A; Emini EA; Gruber WC; Grobbee DE
    N Engl J Med; 2015 Mar; 372(12):1114-25. PubMed ID: 25785969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the pneumococcal vaccine on long-term morbidity and mortality of adults at high risk for pneumonia.
    Johnstone J; Eurich DT; Minhas JK; Marrie TJ; Majumdar SR
    Clin Infect Dis; 2010 Jul; 51(1):15-22. PubMed ID: 20504233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.